Regulus Therapeutics (RGLS) Reports In-Line Q3 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.50), in-line with the analyst estimate of ($0.50).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Qualcomm investor day to detail data center plans Wednesday